Clinical Trial

Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It\'s an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-10; most recent amendment 2025-03-07.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-03-07
Trial Details
NCT Number NCT06593197
Lead Sponsor Dow University of Health Sciences
Conditions Vitiligo
Enrollment 30 participants
Start Date 2025-01-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-11